BioDelivery Sciences International, Inc. (BDSI) Launching ONSOLIS in Canada

BioDelivery Sciences International Inc. is a specialty pharmaceutical company that is commercializing new applications of proven applications. The company is currently focusing its efforts in the areas of pain management and oncology supportive care.

The company today announced that the commercial launch and availability of ONSOLIS (fentanyl buccal soluble film) in Canada will occur this quarter. ONSOLIS is approved in the US and Canada for the management of pain in opioid tolerant, adult patients with cancer. This product will be marketed in Canada by Meda Valeant Pharma Canada Incorporated, a joint venture between BioDelivery Sciences’ commercial partner for ONSOLIS, Meda, and Valeant Canada Limited.

Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical company. In Canada, its portfolio includes products for the treatment of pain and oncology supportive care. This makes them an ideal partner for BioDelivery Sciences International and the commercialization of ONSOLIS.

The Canadian market will be of particular importance to BioDelivery Sciences. That is because ONSOLIS will be among the first products available in the country for the management of pain in patients undergoing cancer treatment that have a tolerance for opioids. The company also plans to introduce ONSOLIS soon in other markets such as Europe, where it is also approved and will be marketed as BREAKYL.

For more information on BioDelivery Sciences International, please visit the company’s website at www.bdsi.com

About MissionIR:

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html